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Incidence and Etiology of Drug-Induced Liver Injury in Mainland China 
 
Abstract 
Background & Aims: We performed a nationwide, retrospective study to determine the 
incidence and causes of drug-induced liver injury (DILI) in mainland China. 
Methods: We collected data on a total of 25,927 confirmed DILI cases, hospitalized from 2012 
through 2014 at 308 medical centers in mainland China. We collected demographic, medical 
history, treatment, laboratory, disease severity, and mortality data from all patients. Investigators 
at each site were asked to complete causality assessments for each case whose diagnosis at 
discharge was DILI (n=29,478) according to the Roussel Uclaf Causality Assessment Method. 
Results: Most cases of DILI presented with hepatocellular injury (51.39%; 95% CI, 50.76–52.03), 
followed by mixed injury (28.30%; 95% CI, 27.73–28.87) and cholestatic injury (20.31%; 95% CI, 
19.80–20.82). The leading single classes of implicated drugs were traditional Chinese medicines 
or herbal and dietary supplements (26.81%) and anti-tuberculosis medications (21.99%). Chronic 
DILI occurred in 13.00% of the cases and, although 44.40% of the hepatocellular DILI cases 
fulfilled Hy’s Law criteria, only 280 cases (1.08%) progressed to hepatic failure, 2 cases underwent 
liver transplantation (0.01%), and 102 patients died (0.39%). Among deaths, DILI was judged to 
have a primary role in 72 (70.59%), a contributory role in 21 (20.59%), and no role in 9 (8.82%). 
Assuming the proportion of DILI in the entire hospitalized population of China was represented 
by that observed in the 66 centers where DILI capture was complete, we estimated the annual 
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incidence in the general population to be 23.80 per 100,000 persons (95% CI, 20.86–26.74). Only 
hospitalized patients were included in this analysis, so the true incidence is likely to be higher. 
Conclusions: In a retrospective study to determine the incidence and causes of drug-induced liver 
injury (DILI) in mainland China, the annual incidence in the general population was estimated to 
be 23.80 per 100,000 persons—higher than that reported from western countries. Traditional 
Chinese medicines, herbal and dietary supplements, and anti-tuberculosis drugs were the leading 
causes of DILI in mainland China.  
Keywords: jaundice; RUCAM, Asia, epidemiology 
Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to 
liver failure and even death.
1-3
 DILI is increasingly appreciated to be one of the most challenging 
diseases for physicians and gastroenterologists. However, the burden of DILI in China, which has 
the world’s largest population, has not been estimated. 
In the west, the incidence of DILI has been estimated to be 1/100,000- 20/100,000 in the 
general population.
2, 4-7
 Two population-based studies conducted in France and Iceland estimated 
the annual incidences of DILI to be approximately 13.9/100,000 and 19.1/100,000 respectively.
8, 9
 
In the United States, the annual incidence of DILI in the general population has been recently 
estimated as 2.7 per 100,000 adults, through surveillance in the state of Delaware.
10
 Also, the 
most common causative drugs were anti-infectious agents, anti-TB drugs and natural herbal 
medicines across various registries.
11
 In the past, epidemiologic surveys of DILI in mainland China 
have been focused on patients from a small number of medical institutions. In 2013, Yuan et al. 
performed a comprehensive database search of Chinese literature (279 studies from 1994 to 
2011) to obtain some relevant data on DILI.
12
 However, their study lacked consistent application 
of standardized causality assessment methods and some critical information (such as outcome) 
was incomplete, which limited the conclusions of the study. To date, epidemiological data on DILI 
from medical centers across mainland China have not been available.   
The multiple clinical presentations of DILI and the lack of specific diagnostic tests for DILI 
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create challenges in studying the epidemiology of DILI. In order to help Chinese clinicians to 
better identify and manage DILI, the first edition of guideline for diagnosis and treatment of DILI 
was issued in 2015 by Chinese Society of Hepatology (CSH), and finally published in 2017 in 
English.
13
 Simultaneously, under the CSH guideline, we carried out a retrospective study covering 
308 medical centers in major cities across mainland China to characterize DILI in hospitalized 
patients including the implicated drugs, its clinical features, and to estimate the incidence of DILI.  
 
Materials and Methods 
A three-year retrospective multicentric study (“DILI-R”) 
Case finding and data collection: This was a retrospective study involving 308 medical 
centers in major cities of mainland China. The protocol for the present study was reviewed and 
approved by the institutional review board at Renji Hospital of Shanghai JiaoTong University, 
Shanghai, China (ClinicalTrials.gov Identifier: NCT02407964). Owing to the retrospective analysis 
of existing administrative and clinical data, the requirement to obtain informed patient consent 
was waived by the institutional review board. 
In each center, the records for the in-patients during a period between January 1, 2012 and 
December 31, 2014 were searched for the following diagnoses at discharge, "drug-induced liver 
injury," "drug-induced hepatitis," "drug-induced cirrhosis," and "drug-induced liver failure," or 
using other diagnostic terms for various types of liver injury that were likely caused by drugs. 
Patients who were admitted to the hospitals for other conditions but developed DILI while 
hospitalized were eligible if the discharge diagnoses indicated a DILI event. Inclusion criteria did 
not include specific cut-off levels for liver chemistries. 
Standardized case report forms (CRFs) were filled out for all cases with help from local senior 
gastroenterologists; demographic details and clinical information were recorded. The Hepatox 
website (www.hepatox.org/), a Chinese nationwide DILI research network resource, was utilized 
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as the data collection platform for participants to submit their DILI cases. Each patient was given 
a unique number allowing identification of multiple visits to different centers or readmissions 
during the 3-year period and thereby avoiding duplication. Patients with hepatocellular 
carcinoma or biliary obstructive processes were excluded. Patients with pre-existing chronic liver 
injury were not excluded if they were considered to have developed superimposed DILI.  
Of the initial 29,478 cases whose diagnosis at discharge was DILI, 80 cases with admission 
date out of range and 2,153 cases with missing data were excluded resulting in 27,245 cases with 
eligible data (Figure 1A).  
The following parameters were collected for all the enrolled patients: (1) Demographics; (2) 
disease history and alcohol consumption history; (3) information about the implicated drug that 
might have caused the liver injury, including the time of onset after starting the drug and the 
time of recovery after stopping the drug; (4) symptoms and signs, including time of occurrence, 
time of disappearance and symptoms at discharge were recorded in detail; (5) serum biochemical 
parameters before and during the DILI event, including values of serum alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), serum total bilirubin (TBil), 
direct bilirubin (DBil), albumin (ALB), globulin (GLO), prothrombin time (PT), international 
normalized ratio (INR), and creatinine (Cr); (6) examinations for excluding other causes of liver 
injury (including hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E 
virus (HEV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes virus, Wilson’s disease, and 
autoimmune hepatitis); and (7) severity and mortality of all enrolled patients during and after 
hospitalization.  
Causality assessment: Investigators at each site were asked to complete causality 
assessment scoring for each case whose diagnosis at discharge was DILI (n=29,478) according to 
the Roussel Uclaf Causality Assessment Method (RUCAM).
14, 15
 Cases with scores greater than or 
equal to 6 (“probable”, n = 13,555) were entered into the study directly. Cases with RUCAM 
scores less than 6 (n=13,690) were further reviewed by a panel of 3 hepatologists with DILI 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
expertise (consistent with the expert opinion method of causality assessment
16
). Cases judged by 
at least two of the three hepatologists as probable DILI (n=12,372) were enrolled in the study. 
Thus, a total of 25,927 eligible DILI cases were enrolled in “DILI-R” (Figure 1A). The distribution of 
RUCAM scores (52.28% for ≥6; 31.14% for 5; 10.83% for 4 and 5.75% for 3) of the enrolled 25,927 
DILI cases are presented in Supplementary Figure 1. The panel did not evaluate why the RUCAM 
scores were calculated as below 6 for the enrolled cases. 
The enrolled cases with RUCAM scores < 6 were similar to those with RUCAM scores ≥ 6 in 
terms of demographic and clinical features (Supplementary Figure 2), liver chemistries 
(Supplementary Figure 3) and etiology (Supplementary Figure 4) supporting the causality 
assessment processes.   
Clinical presentation: The clinical type of DILI was classified by the R value calculated from 
the liver tests obtained at presentation (R-value = serum [ALT/ALT upper limits of normal 
(ULN)]/[ALP/ALP ULN]). Cases were classified as hepatocellular if R value ≥5.0, cholestatic if R 
value ≤2.0, and mixed if R-value was 2.0–5.0.
11
 
Severity of DILI and outcomes: Hy’s Law cases were defined as a patient who experienced 
elevations in serum ALT or AST > 3×ULN and a concomitant rise in serum TBil to > 2× ULN and: (1) 
the implicated drug is known to cause elevated serum ALT or AST >3×ULN, (2) there was no 
evidence of cholestasis (serum ALP activity must be ≤2×ULN). (3) there is no more likely cause of 
liver injury such as viral hepatitis, alcohol abuse, ischemia, or preexisting liver disease.
3
 
The definition of acute liver failure (ALF) includes evidence of coagulation abnormality 
indicated by INR≥ 2.0, signs of hepatic encephalopathy, and TBil≥10× ULN (10 mg/dL or 171 
µmol/L) or successive daily elevations ≥1.0 mg/dL (17.1µmol/L) with an illness of <26 weeks 
duration. Patients may also have ascites and DILI-related dysfunction of other organs.
13
 Chronic 
DILI was defined as: 6 months after the onset of DILI, serum ALT, AST, ALP, or TBil continued to 
remain abnormal, or radiographical evidence of portal hypertension or histological evidence of 
ongoing liver injury.
13
 For the death cases, we categorized DILI as having a primary, a contributory, 
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or no role with the help of local senior gastroenterologists. 
The entire 25,927 DILI cases were used for analysis of demographic and clinical features and 
causes of DILI. Of the 308 involved centers, 66 centers provided all recorded hospitalized DILI 
cases during the 3-year period of observation, and the other 242 centers just provided DILI cases 
from some but not all clinical departments. Therefore, to estimate the incidence of DILI in 
mainland China, only DILI cases from the 66 centers with complete event capture were used. 
There were a total of 13,691 DILI cases collected from these 66 centers between Jan 1, 2012 and 
Dec 31, 2014. A flow diagram summarizing the process of DILI case identification is presented in 
Figure 1A. Geographic distribution of all 308 medical centers that participated in this study 
(including 66 centers that contributed to the incidence dataset) is shown in Figure 1B and 
Supplementary Table 1.  
 
Statistical analysis 
The incidence of DILI in the general population was evaluated as (number of DILI inpatients 
in 66 centers annually ÷ total number of inpatients in 66 centers annually) × (number of 
inpatients nationwide annually ÷ the general population in mainland China annually). 
SAS 9.3 for windows (SAS Institute Inc., Cary, NC, USA) was used for data analysis. Values 
were given as median and interquartile range (IQR) or as percentages where appropriate. 
Between-group differences were assessed using either the Mann-Whitney U test or 
Kruskal-Wallis test. Categorical variables were analyzed with χ
2
 test, CMH-χ
2
 test or Fisher’s exact 
test where appropriate. The two-sided 95% confidence levels (CIs) were determined. Statistical 
tests were interpreted at a two-sided significance level of 5%. 
 
Results  
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Demographic features 
In this study, a total of 25,927 DILI cases among hospitalized patients were collected from 
308 medical centers between January 1, 2012 and December 31, 2014 (Figure 1A). As shown in 
Table 1, men with DILI were found slightly more frequently than females. The highest proportion 
of DILI cases were in patients with ages between 40 and 59 years followed by ages 18-39, ages ≥ 
60 and ages < 18 years old. Thus, DILI in children and teenagers represented the lowest 
proportion of the subjects enrolled. We found that the vast majority (25,113 cases, 96.93%) of 
DILI patients was Han Chinese and only 3.07% (795 cases) were minorities and this is consistent 
with the overall population composition. In addition, our study showed that DILI patients 
appeared most frequently in departments of internal medicine (41.74%; 95% CI 41.14-42.34) and 
infectious diseases (32.59%; 95% CI 32.02-33.16), while only 14.42% (95% CI 13.99-14.85) and 
3.35% (95% CI 3.13 - 3.57) were diagnosed in departments of hepatology and oncology 
respectively (Table 1).  
 
Clinical presentations 
In 25,927 DILI cases, 49.47% (95% CI 48.86- 50.08) had serum ALT≥5×ULN when abnormal 
hepatic biochemical indexes were measured for the first time. Cases with serum ALT≥ 3×ULN and 
<5× ULN and cases with serum ALT<3×ULN formed 16.73% (95% CI 16.27- 17.17) and 33.81% 
(95% CI 33.23 - 34.39) of the cases respectively (Table 1). Most DILI cases were hepatocellular 
injuries (51.39%; 95% CI 50.76 -52.03), following by mixed injury (28.30%; 95% CI 27.73 - 28.87) 
and cholestatic injury (20.31%; 95% CI 19.80-20.82) (Table 1).  
Eighty-seven % (95% CI 86.55 - 87.38) of the 25,927 DILI cases presented as acute DILI (Table 
1). In addition, 13.00% of the DILI cases (95% CI 12.44-13.25) progressed to chronic DILI with 
persistent evidence of liver injury at least 6 months after DILI onset. Follow-up data based on a 
small subset of cases indicated that some patients who were defined as chronic DILI at month 6 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
normalized their liver chemistries after 1- or 2-year’s observation, suggesting delayed recovery 
(Supplementary Figure 5). Of note is that 44.40% (95% CI 43.52 -45.28, n = 5,460) of 
hepatocellular injuries resulted in laboratory values consistent with Hy’s Law (serum ALT > 3 × 
ULN and total serum bilirubin>2 ×ULN) (Table 1). 
Of note, few cases progressed to life-threatening outcomes, which included 280 progressing 
to hepatic failure (1.08%), two undergoing liver transplantation (.01%) and 102 dying (.39%). Of 
102 death cases, DILI was judged to have had a primary role in 72 (70.59%), a contributory role in 
21 (20.59%), and no role in 9 (8.82%) (Table 1). Causes of death, the drugs implicated as causing 
DILI, and the last hepatic biochemistry values obtained prior to death are shown in 
Supplementary Table 2.  
Except for those life-threatening (“fatal”) DILI cases (1.48%), most DILI cases did not 
experience jaundice (80.76%) and only 17.76% cases presented with jaundice (Supplementary 
Figure 6). It was noteworthy that the higher proportions of hepatocellular DILI were found in fatal 
cases (65.67%, P<.0001) and in cases with jaundice (65.09%, P<.0001) than in non-fatal cases or 
in the absence of jaundice (48.53%) (Supplementary Figure 6).  
Latency period was considered as the time span between the start of treatment with the 
implicated drugs and the time that abnormal serum liver chemistries (ALT, AST, ALP or TBil) were 
first detected. In this study, latency period in DILI cases without jaundice was shorter than in 
cases with jaundice (P < .0001) and in fatal cases (P < .0001) (Supplementary Figure 6). 
Additionally, cases with hepatocellular injury displayed longer latency than cholestatic and mixed 
types (P< .0001) (Supplementary Table 3); DILI cases induced by traditional Chinese medicines 
presented with longer latency than cases caused by western medications (P < .0001) and cases 
induced by implicated drugs within three or more classes in combination displayed shorter 
latency than those caused by drugs with single or two classes in combination (P < .0001) 
(Supplementary Table 3).  
Interestingly, we observed that a significant proportion of our cohort, 23.38% (95% CI 22.86 - 
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23.90), had pre-existing liver disease (Table 1). The highest proportion of pre-existing liver disease 
was among the in fatal cases (64.32%), followed by cases with jaundice (29.21%) and cases 
without jaundice (21.34%) (P < .0001) (Supplementary Figure 6). The distribution of pre-existing 
liver disease is presented in Supplementary Figure 7. These results indicated that pre-existing 
liver disease was associated with more severe outcome from DILI.  
 
Effect of age, gender and ethnicity 
Latency, duration of usage of the implicated agents and clinical indicators of DILI patients, 
were compared according to gender, age and ethnicity. As shown in Figure 2, females 
experienced longer latency (P<.0001) than males. Also, female patients had higher serum TBil (P 
<.01), DBil (P < .01), TBA (P < .0001), ALT (P < .0001), AST (P < .0001) and ALP (P < .0001) than 
males. Of note, compared to the DILI cases without jaundice, female gender occupied higher 
frequencies than that of men, either in cases with jaundice (P < .0001) or in life-threatening DILI 
(P < .01) (Supplementary Figure 6).  
As expected, higher values of TBil, DBil, TBA, ALT, AST and GGT (all P <.0001) were found in 
hepatocellular DILI than in cholestatic and mixed DILI and conversely, higher ALP values were 
higher in cholestatic DILI than in other two types of liver injuries (Figure 2). In addition, compared 
with adult patients, liver disorders were relatively milder in children (<18 years old). Also, 
children had a shorter mean latency period (P <.0001) and duration of usage of implicated agents 
(P<.0001), and lower peak levels of TBil, DBil, TBA, ALT, AST and GGT than in adults (P<.0001). As 
expected from continuing bone growth, children generally had higher ALP levels than adults 
(Figure 2). In summary, female and older DILI patients tended to have more severe DILI than male 
and younger individuals.   
Interestingly, we found that the latency period (P <.05) and duration of usage of implicated 
agents (P < .01) was significantly longer in ethnic minorities than in Han Chinese. However, the 
Han Chinese had generally more severe liver injury (TBA, P < .01; ALT, P < .0001; AST, P < .0001 
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and GGT, P < .01) than in ethnic minorities (Figure 2). 
 
Causes of DILI 
As shown in Figure 3A, the implicated drugs were categorized according to their class and 
main clinical indication. Most DILI events were reported to be caused by drugs within single 
classes (82.67%). TCM or HDS (26.81%) and anti-TB drugs (21.99%) were the two leading classes 
of implicated agents. As is well known, TCM and HDS included traditional Chinese medicines, 
natural medicines, Tibetan medicines, Mongolian medicines, health care products, and herbal 
and dietary supplements. TCM and HDS are being used increasingly worldwide, especially in 
China. A high proportion of Chinese prefers to use traditional Chinese medicines based on the 
mistaken belief that these drugs have little or no side effects.  
The anti-TB drugs included isoniazid, rifampicin, pyrazinamide and ethambutol. Besides TCM, 
HDS and anti-TB drugs, other single classes of implicated agents with occurrence >1% included 
antineoplastics or immunomodulators (8.34%), anti-infectious agents (6.08%), psychotropics 
(4.90%), non-sex hormones (3.04%), cardiovascular drugs (2.98%), digestive drugs (2.04%), 
respiratory drugs (1.47%) and musculoskeletal drugs (1.32%). In addition to single agents, 
implicated agents were from two or three classes in 14.06% and 3.27% of DILI patients, 
respectively (Figure 3A).  
Besides analyzing implicated drugs according to their class and main clinical indication, we 
also ranked the incidence of DILI due to specific implicated drugs. Most of the specific implicated 
drugs also belonged to classes of anti-TB drugs or TCM or HDS (Figure 3B).  
 Interestingly, our data showed that DILI due to TCM or HDS was more common in females 
than in males, and DILI due to anti-TB drugs was more common in males than in females 
(Supplementary Figure 8).  
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Estimation of incidence of DILI 
Of the 308 medical centers that participated in this study, only 66 centers provided all 
recorded hospitalized DILI cases during the three-year observation period and could therefore be 
used to estimate the proportion of DILI patients among all inpatients. Specifically, a total of 
8,102,732 individuals from 2012 to 2014 were hospitalized in these 66 centers and 13,691 were 
diagnosed with DILI (Table 2). The location of these participating medical centers is listed in 
Supplementary Table 1. No hospitals from Hong Kong, Macau or Taiwan were included in this 
study. As shown in Table 2, the average percentage of total inpatients with a diagnosis of DILI in 
2012, 2013 and 2014 were calculated to be 1.62‰ (95% CI 1.57-1.67), 1.69‰ (95% CI 1.64-1.74) 
and 1.74‰ (95% CI 1.70-1.79), respectively. The mean percentage was therefore estimated as 
1.69‰ (95% CI 1.66-1.72) of hospitalized patients during the three year interval. Interestingly, 
higher proportions were found in South China (6.53‰) and Southwest China (5.02‰) than in 
other regions (Supplementary Table 4).  
As reported in 2016 by China health and family planning statistical digest (issued by National 
Health and Family Planning Commission),
17
 there were 178.57 million, 192.15 million and 204.41 
million inpatients in 2012, 2013 and 2014 in mainland China, respectively. There were 
approximately 1.354, 1.361 and 1.368 billion inhabitants in 2012, 2013 and 2014 in mainland 
China, respectively, according to the Population Sample Survey conducted by the National Bureau 
of Statistics. Thus, the percentages of inpatients in the general population were calculated as 
13.19%, 14.12% and 14.94% in 2012, 2013 and 2014, respectively (Table 3).  
As described in “materials and methods”, the incidence of DILI was assessed as the 
proportion of DILI cases among inpatients in 66 centers annually × number of inpatients 
nationwide annually ÷ the general population in mainland China. In this case, the annual 
incidence of DILI was calculated as 21.37 per 100,000 (95% CI 18.59 - 24.15), 23.86 per 100,000 
(95% CI, 20.92 - 26.80) and 26.00 per 100,000 (95% CI 22.93 - 29.07) in 2012, 2013 and 2014, 
respectively (Table 3). Accordingly, the annual incidence of DILI increased gradually from 2012 to 
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2014 and the average incidence was estimated as 23.80 per 100,000 (95% CI 20.86 - 26.74).  
 
Discussion 
This nation-wide study for the first time provides an estimate of the burden of DILI in 
mainland China. In our multicenter study involving case records of over 8 million patients from 66 
centers throughout mainland China, 1.69‰ of the patients had a diagnosis of DILI during the 
period between 2012 and 2014. Extrapolating this information to the data from the National 
Health and Family Planning Commission, we estimated the incidence of DILI to be 23.80 per 
100,000 populations. In mainland China, health care of Chinese inhabitants has been covered by 
the public medical service system, medical insurance system and the rural cooperative medical 
system since 2003. This means that most DILI patients recognized to have DILI are referred to the 
hospitals for management. In addition, in mainland China, hepatoprotective agents are generally 
administered to hospitalized patients with DILI. Because of this, we believe that most patients 
discovered to have DILI in mainland China were hospitalized during the time interval we 
examined. However, there was likely a proportion of DILI patients with a mild or moderate liver 
injury who were either not recognized to have DILI or were managed as outpatients and were 
therefore not considered in our study. In addition, in underdeveloped parts of the country not 
well covered by our survey, there is a higher than average incidence of diseases requiring 
hepatotoxic drug treatment, such as tuberculosis, viral hepatitis and even HIV/AIDS.
18-20
 
Therefore, the actual DILI incidence in mainland China is very likely higher than our estimate of 
23.80 per 100,000 in general population, which was still higher than that estimated in Iceland 
(19.1/100,000)
 7
, France (13.9/100,000),
9
 the United states (2.7/100,000),
10
 Spain (3.42/100,000)
21
 
and Sweden (2.4/100,000)
22
 (Table 4). 
In this study, 44.40% of those with hepatocellular pattern met the threshold of ‘Hy’s law’. 
Overall, 17.76% of cases developed jaundice, 1.08% progressed to hepatic failure and 0.4% died 
or had transplantation as a consequence (Table 1 and Supplementary Figure 6). Of those who 
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died, DILI was assessed as a primary cause of death in 70.59% and as contributing to death in 
another 20.59% (Table 1). Our study did not have inclusion criteria based on liver chemistry 
values, and therefore, our cohort of DILI patients included cases of mild liver injury not included 
in other registries. However, our incidence of chronic DILI was comparable to that has been 
reported in other registries (Table 4). Moreover, almost half of our cases with hepatocellular DILI 
fulfilled biochemical criteria for Hy’s Law indicating potentially life-threatening liver injury. It is 
therefore interesting that the DILI fatality rate in our study was much lower than has been 
observed in other registries
21, 23-26
. The reasons for this discrepancy are not clear, but the dilution 
with a large number of milder cases, less availability of liver transplantation (considered a fatality 
equivalent in other studies) and possibly the frequent administration of hepatoprotective agents, 
may have contributed to the lower DILI fatality rate in China. Our observations may need to be 
considered when interpreting the significance of Hy’s Law cases observed in clinical trials 
involving Chinese participants. 
Whether gender is a risk factor for susceptibility to DILI is still controversial. In this study, 
male patients accounted for just over half the cases of DILI. Though females are suggested to 
have a higher risk of idiosyncratic DILI than males in many retrospective studies,
8, 27-30
 females 
have been reported to have increased,
8, 26, 27, 31
 unchanged,
9, 30
 or even decreased
12, 21
 incidence 
of DILI (Table 4). In China, it was estimated that 918,000 individuals suffered from tuberculosis 
(TB) (including TB co-infected with HIV) with overall incidence of 67/100,000 population, which 
accounted for 8.65% of the world’s reported cases of TB in 2015 (WHO Global tuberculosis report 
2016).
32
 Among TB patients, male to female ratio was 2.1:1.
32
 A very similar gender distribution 
ratio was found in our study among patients with DILI due to TB treatments (65.6% for men vs. 
34.4% for women) (Supplementary Figure 9) suggesting susceptibility was not affected by gender. 
Although men made up a slightly larger proportion of the overall DILI population, more severe 
clinical manifestations were observed in females, as shown by higher serum levels of TBil, DBil, 
TBA, ALT, AST and ALP (Figure 2), and higher frequency of DILI with jaundice (Supplementary 
Figure 6), which is in line with reports by others.
21, 31
 We also observed that 4.29% (95% CI 
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4.04-4.54) of DILI patients in our study were children and teenagers (<18-year-old) and that DILI 
severity as indicated by peak liver chemistries was lower in children than that in adults (Table 1 
and Figure 2). Differences of implicated drugs, dosing, pharmacokinetic factors, or inherent 
differences in DILI susceptibility may contribute to the observed differences between children 
and adults in DILI phenotypic characteristics.  
As reported by the western studies, acute liver failure was most associated with use of 
non-steroidal anti-inflammatory drugs (NSAIDs), anti-infective drugs, and herbs and dietary 
supplements (HDS).
13, 33, 34
 In mainland China, as indicated in our data (Figure 3), TCM or HDS and 
anti-tuberculosis drugs were the major offending agents of DILI.  
TCM or HDS were the single drug class implicated in this study (Figure 3). In fact, despite the 
recent recognition of the potential hepatotoxicity of HDS, usage of HDS has increased 
tremendously worldwide, not only in Asian countries (such as China, Korea, Japanese and South 
Asian countries), but also in the western countries. Individuals who consume these HDS usually 
choose to ignore or be unaware of the potential side effects. Additionally, compared to 
conventional prescription medications, the absence of regulatory guidelines for the production 
and sale of herbal compounds further contribute to their overuse. For instance, it is not generally 
known among the Chinese population that natural medicines, such as the single herbs Heshouwu 
or Leigongteng, or the composite agents Xiao-Chai-Hu-Tang (XCHT) have been associated with 
DILI, although laboratory studies have also shown that these treatments cause immune 
activation, metabolic disorders, apoptosis and damage to liver cells.
35-39
 We believe that such 
analyses of Chinese herbal medicines are essential and urgent in order to find out whether these 
and other toxic ingredients are present. 
In addition to TCM or HDS, over 20% of DILI cases were attributed to anti-TB drugs (Figure 3), 
which is consistent with China having the second highest TB burden worldwide. The cornerstone 
of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and 
ethambutol. All these anti-TB drugs have hepatotoxicity potential and could lead to DILI during 
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anti-tuberculosis treatment, which commonly leads to interruption of anti-TB treatment and may 
promote antibiotic resistance.
40
 It is estimated that in China, 5.7% new TB cases and up to 26% 
among previously treated TB cases carry multidrug-resistance (MDR-TB).
41
 
Liver injury caused by antineoplastic or immunomodulators includes hepatocyte necrosis, 
hepatic steatosis, hepatic mitochondrial injury, cholestasis and vascular injury.
42-45
 Consistent 
with the previous reports, we found the rate of DILI caused by antineoplastic or 
immunomodulators was the third leading cause of DILI, just behind TCM or HDS and anti-TB 
drugs. 
In this study, 6.08% of DILI cases were attributed to anti-infectious agents including 
antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals, and antivirals (in the present 
study, anti-TB drugs were given a separate classification). In the West, anti-infectives are the 
leading drugs associated with DILI. Interestingly, the percent of DILI cases due to anti-infection 
agents in our study seems low since antibiotics are used more frequently in China than in any 
other country. For example, according to one survey approximately two-thirds of inpatients in 
China were administered antibiotics, which is twice that reported in many other countries.
46
  
Antibiotic overuse has become a severe issue in China. A joint effort from authorities, physicians, 
patients and media should be taken to improve public knowledge of both risks and benefits of 
anti-infective therapy.  
In our study, we had no entrance criteria based on liver chemistries so may have included 
more relatively mild cases than in other registries. Additionally, our relatively low enrollment of 
children and teenagers (<18 years old) may be related to the relatively limited number of 
pediatric hospitals participating in the study.  
In summary, in the largest registry of its kind, we have provided a complete characterization 
of DILI in mainland China. We conclude that DILI has a higher incidence in mainland China than in 
western countries and that TCM, HDS and anti-tuberculosis drugs are the leading categories of 
agents causing DILI.  
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Figure legends 
Figure 1. The centers participating in DILI patient recruitment. (A) A flow diagram for DILI patient 
recruitment in this study. (B) Geographical distribution of all 308 participating medical centers. 
*Of the 308 involved centers, only 66 centers provided all recorded hospitalized DILI cases during 
3-year observation (red dots). Thus, DILI cases from these 66 centers were used to assess the 
diagnostic rate of DILI in this study, since all inpatients were screened for the occurrence of DILI.  
 
Figure 2. Comparison of latency, duration of usage of implicated agents, and maximal values of 
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clinical chemistries during the course of the injury among patients according to gender, age and 
ethnicity. Clinical indicators included serum total bilirubin (TBil), direct bilirubin (DBil), total bile 
acid (TBA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP) and γ glutamyl transpeptidase (GGT). All data were shown as median and IQR 
and asterisks indicated significant levels by either the Mann-Whitney U test or the Kruskal-Wallis 
test where appropriate (2-tailed; *, P< .05; **, P< .01; ***, P< .0001).  
 
Figure 3. Causes of DILI in this study. (A) Implicated DILI drugs were categorized according to their 
therapeutic class source and main clinical indications. Percentages of patients with one or more 
implicated classes of agent(s) are also shown. (B) Implicated specific DILI drugs were ranked 
according to single agent, combination of two agents and combination of three or more agents. 
TCM, traditional Chinese medicine; HDS, herbal and dietary supplements; *Anti-infectious agents 
included antibiotics, antiviral and antifungal drugs, but not anti-tubercular agents. 
#
sex hormones 
were not included. 
ξ
The detailed information is unknown. 
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Table 1. Demographic and Clinical features of 25,927 DILI cases from 308 centers nationwide 
 Number % 95% CI 
Gender
a
    
  Male 12,930 50.83 [50.22, 51.45] 
  Female 12,507 49.17 [48.55, 49.78] 
Age
b
    
≥60 5,694 22.09 [21.58, 22.60] 
40-59 11,015 42.73 [42.13, 43.34] 
18-39 7,962 30.89 [30.33, 31.45] 
<18 1,105 4.29 [4.04, 4.54] 
Ethnicity
c
    
  Han 25,113 96.93 [96.72, 97.14] 
  Non-han 795 3.07 [2.86, 3.29] 
Department of diagnosis    
Internal medicine 10,822 41.74 [41.14, 42.34] 
Infectious diseases 8,450 32.59 [32.02, 33.16] 
Hepatology 3,738 14.42 [13.99, 14.85] 
Oncology 869 3.35 [3.13, 3.57] 
Others 2,048 7.90 [7.57, 8.23] 
Pre-existing liver diseases    
Yes 6061 23.38 [22.86, 23.90] 
No 19866 76.62 [76.10, 77.14] 
Initial serum ALT values
d
    
≥ 5× ULN 12826 49.47 [48.86, 50.08] 
≥3× ULN and < 5 × ULN 4335 16.72 [16.27, 17.17] 
< 3× ULN  8766 33.81 [33.23, 34.39] 
Clinical types of DILI
e
    
Hepatocellular injury (R≥5) 12,298 51.39 [50.76, 52.03] 
Conform to Hy’s law 5,460 44.40 [43.52,45.28] 
Others 6,838 55.60 [54.72,56.48] 
Cholestatic injury(R≤2)  4,860 20.31 [19.80, 20.82] 
Mixed injury (2<R<5) 6,771 28.30 [27.73, 28.87] 
Acute/chronic DILI    
Acute DILI 22,556 87.00 [86.55, 87.38] 
Chronic DILI  3,371 13.00 [12.44, 13.25] 
Life-threatening outcomes    
Progress to acute liver failure
f
 280 1.08 [0.95, 1.21] 
Undergoing liver transplantation 2 0.01 [0.00, 0.02] 
Death 102 0.39 [0.32, 0.47] 
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DILI had primary role 72 70.59 [61.75, 79.43] 
DILI had contributory role 21 20.59 [12.74, 28.44] 
DILI had no role 9 8.82 [3.32,14.33] 
a
Gender information of 490 cases was missing or unknown. 
b
Age information of 151 cases was 
missing or unknown. 
c
Ethnicity information of 19 cases was missing or unknown.
d
 ALT values 
when abnormal hepatic biochemical indexes occurred for the first time. 
e
In 1,998 cases “R” value 
could not be calculated as ALP value was missing when abnormal ALT or AST occurred for the first 
time. 
f
ALF cases who received liver transplantation or died during hospitalization were not 
included. 
 
 
Table 2. Evaluation of the proportion of DILI cases among inpatients in mainland China based on 
“DILI-R” study 
Years Number of 
inpatients 
Number of DILI 
inpatients 
Proportion of 
DILI (‰)
a
 
95% CI 
2012 2,373,358 3,845 1.62 [1.57, 1.67] 
2013 2,746,378 4,643 1.69 [1.64, 1.74] 
2014 2,982,996 5,203 1.74 [1.70, 1.79] 
Total 8,102,732 13,691 1.69 [1.66, 1.72] 
a
The proportion of DILI = number of DILI inpatients in 66 centers annually ÷ number of inpatients 
in 66 centers annually. 
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Table 3. Estimation of the annual incidence of DILI in the general population of mainland China between 2012-2014  
Years Inpatients nationwide
a
 
(million) 
the general 
population in 
mainlandChina
b
 
(billion) 
Percentage of inpatients 
 In the general population 
annually (%)  
Estimated DILI incidence
c
 in 
the general population (per 
100,000) 
95% CI 
2012 178.57 1.354 13.19% 21.37 [18.59, 24.15] 
2013 192.15 1.361 14.12% 23.86 [20.92, 26.80] 
2014 204.41 1.368 14.94% 26.00 [22.93, 29.07] 
Average 191.71 1.361 14.08% 23.80 [20.86, 26.74] 
a
The data were cited from China health and family planning statistical digest 2016, which was issued by the National Health and Family Planning 
Commission. 
b
The data were estimated by the Population Sample Survey annually and cited from National Bureau of Statistics of the People’s Republic 
of China (http://data.stats.gov.cn/index.htm).
 c
The incidence of DILI in the general population = the proportion of DILI cases in inpatients in 66 centers 
annually×(number of inpatients nationwide annually ÷ the general population in China mainland). 
 
 
 
 
 
 
Table 4. Clinical features of DILI in our study vs. reported from 7 other countries.  
Study Iceland
8
 France
9
 United States
23
 Spain
21
 Sweden
24
 India
25
 Japan
26
 China 
(current study) 
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Study design Prospective Prospective Prospective Prospective Retrospective Retrospective Retrospective Retrospective 
Duration 
(years) 
2010-2011 1997-2000 2004-2013 1994-2004 1970-2004 1997-2008 1997-2006 2012-2014 
Incidence per 
year 
19.1 per 
100,000 
inhabitants 
13.9 per 100,000 
inhabitants 
2.7 per 100,000 
adults in 
Delaware
10
 
3.42 per 100,000  
inhabitants
22
 
2.4 per 
100,000 
person
29
 
N/A
a
 N/A 23.80 per 100,000 
inhabitants 
(estimated) 
Number of 
cases 
96 34 899 461 784 313 1676 25,927 
% Female 56.25% 64.70% 59% 48.65% 57.7% 42% 57% 49.17% 
Dominated age 
range 
40-59 Y/O
b
 ≥50 Y/O N/A ≥60 Y/O N/A N/A 50-69 Y/O 40-59 Y/O 
% Chronic 7% N/A 18% 10.31% N/A 0.32% N/A 13.00% 
HC/Chol/Mix
c
 42%, 32%, 
26% 
47.1%, 20.6%, 
26.5%  
54%, 23%, 23% 57.8%, 20.0%, 
22.2%  
52.2%, 26,3%, 
21.5% 
N/A 59%, 20%, 21% 51.39%, 20.31%, 
28.30% 
Fatality (%) 1.04% 5.88% 6% 5.38% 9.18% 17.3% 0.4% 0.39% 
Top implicated 
drugs (%) 
Antimicrobials 
(37.0%), HDS
d
 
(16.0%), 
NSAIDs (6%)  
anti-infectious 
(25.0%), 
psychotropic 
(22.5%), 
hypolipidemic 
(12.5%), and 
NSAIDs
e
 drugs 
(10.0%) 
antimicrobials 
(45.4%), HDS 
(16.1%), CVS
f
 
drugs (9.8%), 
CNS
g
 drugs 
(9.1%) 
amoxicillin/clavula
nate (13.23%), TB
h
 
drugs (6.95%), 
ebrotidine (4.93%) 
 
antibiotics 
(27.04%), 
NSAIDs 
(4.85%), 
anesthetics 
(1.91%) 
TB drugs 
(57.8 %), 
phenytoin 
(6.7 % ), 
olanzapine 
(5.4%), 
dapsone (5.4%) 
Antibiotics (14.3%), 
psychotropics and 
neurological drugs 
(10.1%), dietary 
supplements 
(10.0%) 
TCM
i
 or HDS 
(26.81%), 
tuberculostatics 
(21.99%), 
antineoplastic or 
immunomodulators 
(8.34%) and anti-
infectious (6.08%) 
a
N/A, not available; 
b
Y/O, years old; 
c
HC/Chol/Mix, hepatocellular injury/cholestatic injury/mixed injury; 
d
HDS, herbal and dietary supplements; 
e
NSAIDs, non-steroidal anti-inflammatory drugs; 
f
CVS, cardiovascular system; 
g
CNS, central nervous system; 
h
TB, tuberculosis; 
i
TCM, traditional Chinese 
medicine. 
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Supplementary data for manuscript entitled “Incidence and Etiology of 
Drug-Induced Liver Injury in Mainland China” 
 
Supplementary Table 1. The Recruitment at the 308 centers (including 66 centers specific for 
assessing of diagnostic rate of DILI) participating in the study 
Regions/Provinces 308 centers recruited in 
the study 
66 centers with complete 
enrollment of all DILI cases 
North China 59 14 
Beijing 6 1 
Tianjin 5 0 
Inner Mongolia 13 4 
Hebei 9 0 
Shanxi 16 4 
Henan 10 5 
Northeast China 25 7 
Heilongjiang 15 3 
Jilin 9 3 
Liaoning 1 1 
East China 97 35 
Shanghai 16 8 
Shandong 23 6 
Zhejiang 19 2 
Jiangsu 13 9 
Anhui 16 5 
Fujian 4 3 
Jiangxi 6 2 
Central China 50 4 
Hubei 34 3 
Hunan 16 1 
South China 17 2 
Guangdong 12 2 
Guangxi 3 0 
Hainan 2 0 
Southwest China 19 2 
Sichuan 5 2 
Chongqing 3 0 
Guizhou 3 0 
Yunnan 8 0 
Northwest China 41 2 
Shanxi 21 0 
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Ningxia 1 0 
Gansu 4 1 
Qinghai 3 0 
Xinjiang 11 1 
Xizang 1 0 
Total 308 66 
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Supplementary Table 2. Causes of death, implicated drugs of causing DILI, and the last hepatic biochemistry values obtained prior to death in these death cases 
with DILI 
Case NO. Causes of death Implicated drugs in causing DILI 
ALT  
(IU/L) 
AST  
(IU/L) 
GGT  
(IU/L) 
ALP 
 (IU/L) 
TBA 
 (μM) 
TBIL 
(μM) 
DBIL 
(μM) 
TP 
(g/L) 
ALB 
(g/L) 
DILI-induced liver failure played a primary role in these death cases (n=72) 
368082 DILI Oxcarbazepine/Carbamazepine 268 90 97 99 N/A 257 149 53 33
339001 DILI Methimazole/Metoprolol 31 46 34 204 N/A 317 147 77 28
335063 DILI Cis-platinum 29 45 33 49 N/A 190 154 48 23
335027 DILI Cis-platinum/Arsenic trioxide 91 90 217 343 N/A 68 48.4 51 30
321344 DILI TCM(ingredient unknown)  27 177 68 60 229 374 279 40 26
320002 DILI TCM (Ku-Huang herbal injection) 60 163 530 576 84 333 184 62 23
316007 DILI Isoniazid/Pyrazinamide 142 342 217 N/A N/A 345 292 61 27
309398 DILI TCM(ingredient unknown) 465 281 82 93 99 277 159 60 32
309345 DILI TCM(ingredient unknown) 300 385 27 85 69 135 83 37 20
309343 DILI TCM(Sheng-Mai-Ying) 2583 573 59 216 458 182 80 52 30
309144 DILI Amidopyrine compound 2841 901 58 201 220 106 43 53 30
309142 DILI TCM(ingredient unknown)/Levofloxacin/Sulbactam 875 944 137 215 239 258 179 61 27
309136 DILI Cold medication (details unknown) 105 132 37 47 56 258 221 38 28
308108 DILI TCM(ingredient unknown)/Acarbose 174 217 219 252 226 320 204 43 23
289185 DILI Esomeprazole 29 129 566 326 207 112 85 48 17
284044 DILI Sulpiride 72 98 41 127 49 120 71 61 19
275046 DILI Isoniazid/Ethambutol /Pyrazinamide/Rifampicin 322 433 47 184 83 331 209 56 28
274901 DILI Imatinib 234 330 44 140 176 459 174 51 31
274886 DILI TCM(ingredient unknown) 155 334 25 162 214 770 337 61 31
274819 DILI Antituberculosis drugs (details unknown) 931 490 31 170 188 486 220 56 32
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254050 DILI TCM(ingredient unknown) 142 107 25 134 233 425 273 58 27
231293 DILI TCM(ingredient unknown) 100 150 34 126 409 681 264 46 27
225001 DILI Rifampicin 1444 3206 N/A 350 95 76 47 65 38
214007 DILI TCM(ingredient unknown)/allopurinol 98 124 379 741 207 375 314 42 27
206016 DILI TCM(ingredient unknown) 64 58 46 125 18 274 130 54 27
202010 DILI TCM(ingredient unknown) 161 91 121 182 140 432 357 33 20
191059 DILI TCM(Tu-San-Qi) 47 80 138 159 N/A 259 237 N/A 26
191057 DILI Anti-tumor drugs(details unknown) 54 1701 1867 435 N/A 320 274 N/A 27
174064 DILI TCM(Tu-San-Qi, yam chip) 73 128 127 124 175 391 281 45 32
161094 DILI Rifampicin 288 55 38 121 N/A 267 83 51 28
146037 DILI TCM(ingredient unknown) 404 177 37 78 162 373 186 54 37
146034 DILI TCM(ingredient unknown) 455 267 36 167 N/A 342 157 69 26
144098 DILI TCM(ingredient unknown) 230 111 26 109 246 228 123 54 31
140222 DILI TCM(ingredient unknown) 82 187 34 258 307 427 280 69 29
140219 DILI TCM(ingredient unknown) 12 88 33 84 138 486 164 53 33
140170 DILI Propylthiouracil 46 50 N/A N/A N/A 102 79 53 29
140152 DILI Antituberculosis drugs (details unknown) 795 1391 67 187 229 360 225 55 29
140141 DILI TCM(ingredient unknown) 961 1811 382 173 52 656 404 53 32
140099 DILI Isoniazid/Eethambutol/Pyrazinamide/Rifapentini 20 89 53 97 94 92 64 53 27
122002 DILI Amlodipine 534 565 91 134 9 39 18 59 24
108036 DILI Methylprednisolone 50 135 529 1275 23 1993 118 59 24
107014 DILI TCM(ingredient unknown) 250 77 500 271 74 122 116 52 30
098074 DILI TCM(ingredient unknown) 817 593 64 122 255 387 186 54 28
053166 DILI Rifampicin/Isoniazid/Pyrazinamide/Ethambutol 299 189 39 107 N/A 312 143 42 28
050257 DILI desensitizer (ingredient unknown) 712 54 196 189 280 427 270 47 31
050131 DILI TCM(ingredient unknown) 150 124 140 146 247 581 312 53 33
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
050105 DILI Ethambutol /Pyrazinamide/Rifampicin 124 140 80 154 132 352 174 49 19
048094 DILI TCM (Radix euphorbiae lantu) 163 78 642 210 112 853 375 44 16
048092 DILI TCM(Si-Xiao-Wan) 79 44 80 99 90 694 398 53 19
048089 DILI Dexamethasone/TCM(ingredient unknown) 61 32 331 169 296 694 398 53 21
048071 DILI TCM(Compound cantharidin capsule) 79 173 773 143 102 249 128 57 23
048020 DILI TCM(ingredient unknown) 39 67 13 80 139 397 198 39 18
048019 DILI TCM(Xiao-Cai-Hu-tang) 83 216 66 131 149 379 163 52 26
032004 DILI Isoniazid/Ethambutol/Pyrazinamide/Rifampicin 1079 2541 76 158 160 273 117 65 25
027668 DILI Antituberculosis drugs (details unknown) 339 337 91 185 333 429 143 41 28
021002 DILI Methotrexate/Cyclophosphamide/Etoposide 30 125 163 422 N/A 169 165 37 19
019041 DILI TCM(ingredient unknown) 192 213 60 156 226 364 216 77 21
016021 DILI TCM(ingredient unknown) 1082 957 130 95 N/A 339 171 61 30
016008 DILI Trazodone/Risperidone 2029 3189 188 5400 N/A 166 130 60 36
009057 DILI TCM(ingredient unknown) 126 336 488 1246 238 528 487 39 22
008038 DILI TCM(ingredient unknown) 41 83 33 44 289 492 375 45 30
007325 DILI TCM(Tripterygium wilfordii)/Methylprednisolone 510 778 211 143 350 485 261 52 24
007123 DILI Glucocorticoid/Ciclosporin/Mycophenolate 418 110 72 102 304 540 333 39 28
005082 DILI TCM(ingredient unknown) 68 68 68 108 109 390 209 52 25
003664 DILI TCM(ingredient unknown) 52 121 1433 932 76 494 371 64 28
003470 DILI Isoniazid/Ethambutol/Pyrazinamide/Rifampicin 5 43 390 643 89 183 161 38 21
003435 DILI Metoprolol/Warfarin/Sertraline 684 841 241 137 287 300 215 64 34
003277 DILI Paracetamol/Pseudoephedrine  1147 493 1181 1503 254 547 433 54 29
003218 DILI Isoniazid/Rifampicin/Pyrazinamide 127 136 125 179 276 445 343 55 27
003094 DILI Pyrazinamide/Isoniazid/Rifampicin 161 64.7 90 172 234 409 125 66 37
003036 DILI TCM(ingredient unknown) 496 242 65 149 219 533 385 53 36
140292 DILI TCM(ingredient unknown) 228 325 226 149 327 388 254 75 33
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DILI played a contributory role in these death cases (n=21) 
320029 respiratory failure, DILI  Cefotiam  32 45 121 250 6 15 6 63 32
335007 Acute lymphoblastic leukemia, DILI Anti-tumor drugs(details unknown) 41 69 522 394 N/A 44 32 63 34
320006 Coronary heart disease, DILI Levofloxacin 14 96 123 167 13 54 29 61 19
309237 Liver cirrhosis, DILI TCM(ingredient unknown) 52 80 20 196 102 55 26 56 22 
320003 Acute pancreatitis, DILI TCM(Ai-Di injection) 27 46 560 516 15 9 3 68 32
287005 Cerebral infarction, DILI TCM(ingredient unknown)/Warfarin/Trimetazidine 57 60 53 120 7 29 18 70 27
272084 Lung cancer, DILI Cis-platinum 72 49 55 78 4 11 5 92 27
188070 Exfoliative dermatitis, Renal failure, DILI Diclofenac 62 26 152 147 4 8 5 63 26
140255 Lung cancer, Diabetes, DILI Gemcitabine 82 48 N/A N/A 7 12 4 56 29
126033 Myocardial infarction, DILI Adenosine Cyclophosphate 19 43 44 579 5 27 10 59 32
032329 TB, respiratory failure, DILI Isoniazid/Ethambutol/Pyrazinamide/Rifampicin 183 189 116 253 4.7 13 11 59 30
027110 AIDS, opportunistic infections, DILI Lamivudine/Stavudine/Efavirenz 144 248 328 405 N/A 27 5 55 19
013012 TB, respiratory failure, DILI Antituberculosis drugs (details unknown) 79 141 116 458 N/A 22 11 56 24
008006 Pulmonary infection, heart failure, DILI Teicoplanin/Clindamycin/Meropenem/moxifloxacin 93 83 175 201 2 28 17 56 32
007140 Intracranial infection, DILI TCM/Cefepime/Ceftriaxone/midazolam/Valproic acid 560 398 188 81 12.7 31 28 46 13
003494 Gastric cancer, DILI Anti-tumor drugs(details unknown) 160 56 225 133 5 20 11 58 36
001049 Prostatic cancer, DILI Triptorelin/Bicalutamide/Zoledronic acid 81 132 273 490 N/A 40 7 51 26
320024 Intestinal tumor, DILI Cefotiam 35 106 263 408 38 46 28 45 25
140194 Pulmonary infection, Septic shock, DILI Antibiotic(details unknown) 47 116 N/A 232 239 61 46 60 24
001158 Septic shock, heart failure, DILI TCM(ingredient unknown) 214 758 263 262 138 31 23 46 28
335008 Myeloid leukemia, DILI Antineoplastic drug (details unknown) 263 305 586 310 N/A 27 18 67 30
DILI had no role in these death cases (n=9) 
335050 Acute myeloid leukemia Hydroxycarbamide/Voriconazole/Biapenem/Teicoplanin 27 41 91 82 N/A 24 8 56 42
335003 Acute myeloid leukemia Homoharringtonine/Cytarabine/Arsenic trioxide 18 12 50 55 N/A 5 3 51 28
335009 Acute non-gonobocytic leukemia, DIC Voriconazole/Cytarabine/Homoharringtonine 59 17 73 55 N/A 14 8 53 33
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284033 Pulmonary malignancy Valproic acid 20 28 188 132 3 12 7 71 40
262001 cerebral infarction, acute rental failure Anti-infectious agents (details unknown) 5 42 128 101 35 30 15 60 28
229046 Interstitial pneumonia, SLE, DIC Methylprednisolone/Ganciclovir/Ciclosporin 34 22 457 124 23 20 8 48 24
216015 Breast cancer Navelbine 37 31 56 103 5 18 6 62 34
111003 Chronic myelogenous leukemia Methotrexate/Cytarabine 53 32 157 63 7 11 5 63 36
007184 Lung cancer Navelbine/Cis-platinum/Cefotiam/Pantoprazole 35 51 79 98 1 12 6 67 33
Clinical indicators included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), 
total bilirubin (TBil), direct bilirubin (DBil), total bile acid (TBA), total protein (TP) and albumin (ALB). TCM, traditional Chinese medicines; TB, tuberculosis; DILI, 
drug-induced liver injury; SLE, systemic lupus erythematosus; DIC, disseminated intravascular coagulation; N/A, not available.  
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Supplementary Table 3. Comparison of latent periods among different clinical types of DILI and 
different categories of implicated drugs 
 Latent period (days) 
Median (IQR) 
P value 
Clinical types of DILI  < .0001 
Hepatocellular injury (R≥5) 39.00 (20.00 - 82.00)  
Cholestatic injury (R≤2) 30.00 (11.00 - 70.00)  
Mixed injury (2<R<5) 31.00 (13.00 - 70.00)  
Origins of Implicated drugs  < .0001 
Traditional Chinese medicines 44.00 (24.00 - 88.00)  
Western medications 30.00 (12.00 - 67.00)  
Classes of implicated drugs  < .0001 
Single class 36.00 (17.00 - 75.00)  
Two classes in combination 32.00 (13.00 - 75.00)  
Three or more classes in combination 33.00 (13.00 - 71.00)  
 Note: Between-group differences were assessed using the Kruskal-Wallis test. IQR, interquartile 
range. P-values (two-tailed) < .05 were considered significant. 
 
 
 
Supplementary Table 4. The number (n) and proportion (‰) of DILI cases from all inpatients in 
seven geographical zones of mainland China 
Geographic region 
Inpatients  
(n) 
DILI patients  
(n) 
proportion of 
DILI (‰) 
95% CI 
Northeast China  1196360 1104 0.92 [0.87, 0.98] 
North China  1162899 3197 2.75 [2.65, 2.84] 
Eastern China 4719372 6573 1.39 [1.36, 1.43] 
South China 186527 1218 6.53 [6.16, 6.90] 
Central China 394783 505 1.28 [1.17, 1.39] 
Northwest China 320533 480 1.50 [1.36, 1.63] 
Southwest China 122258 614 5.02 [4.63, 5.42] 
Total mainland China  8102732 13691 1.69 [1.66, 1.72] 
 
Supplementary Figure 1 
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Supplementary Figure 1. The distribution of RUCAM scores of 25, 927 DILI cases collected in our 
study.  
 
Supplementary Figure 2 
 
Supplementary Figure 2. Comparison of demographic and clinical features between two DILI 
subpopulations with RUCAM ≥6 and RUCAM <6. 
 
Supplementary Figure 3 
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Supplementary Figure 3. Comparison of main liver function indicators between two DILI 
subpopulations with RUCAM ≥6 and RUCAM <6. Values of total bilirubin (TBil), alanine 
aminotransferase (ALT) and alkaline phosphatase (ALP) were indicated when abnormal hepatic 
biochemical indexes occurred for the first time and shown as median and interquartile range. 
 
Supplementary Figure 4 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
 
Supplementary Figure 4. Comparison of the implicated drug classes (A) and individual agents (B) 
between two DILI subpopulations with RUCAM ≥6 and RUCAM <6. *Anti-infectious agents 
included antibiotics, antiviral and antifungal drugs, but not anti-tubercular agents. 
ξ
The detailed 
information is unknown. 
Supplementary Figure 5 
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Supplementary Figure 5. Follow-up survey of some chronic DILI cases in the study. Values (A) and 
percentages of normalization (B) of ALT, ALP and TBil at the time points of 1- and 2-year follow-up 
for some of chronic DILI cases were presented. ALT, ALP and TBil were shown as median and 
interquartile range in (A). n.s., no significance.  
 
Supplementary Figure 6 
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Supplementary Figure 6. Comparison of demographic and clinical features among DILI cases 
without jaundice (W/O jaundice, n=20,938), DILI cases with jaundice (W/ jaundice, n=4,605) and 
life-threatening (“fatal”) DILI (n=384). Life-threatening DILI cases included 280 cases of 
progression to hepatic failure, 2 liver transplantations and 102 deaths. ALT/AST/ALP values used 
are the maximal values observed in each case during the course of the injury. Age, latency, ALT, 
AST and ALP values are shown as median and interquartile range (IQR) and between-group 
differences were assessed using either the Mann-Whitney U test or Kruskal-Wallis test. Category 
variables were analyzed with χ
2
 test or Fisher’s exact test where appropriate. P-values (two-tailed) 
< .05 were considered significant (*, P < .05; **, P < .01; ***, P < .0001). n.s., no significance. 
Supplementary Figure 7 
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Supplementary Figure 7. The distribution of DILI cases with pre-existing liver diseases in the 
study.  
Supplementary Figure 8 
 
Supplementary Figure 8. Comparison of the implicated drug classes of DILI between men and 
women. (A) Comparison of frequencies of TCM or HDS used only, western medicine used only 
and mixed drugs used between two genders. (B) anti-TB drugs were more used by males than 
females. P-values (two-tailed) < .05 were considered significant (***, P < .0001).  
 
Supplementary Figure 9 
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Supplementary Figure 9. Gender distribution in DILI patients with tuberculosis in our study. A 
total of 7, 594 cases were diagnosed as tuberculosis, in which gender information of 132 cases 
was missing or unknown.  
